Integrating Evidence to Enhance Treatment Approaches for VMS and Sleep

This final episode highlights how NIRVANA’s combination of objective and subjective data demonstrates meaningful reductions in wakefulness, awakenings, and arousals, complementing earlier OASIS results and advancing the science of menopause-related sleep research. These findings may influence future guideline considerations and enrich provider–patient discussions about addressing nighttime symptoms more proactively. The conversation closes by noting that with FDA approval and a growing evidence base, clinicians now have a more robust and targeted option for treating both vasomotor symptoms and sleep disturbance.